Business Wire

SAUDI-MINISTRY-ECONOMY

25.1.2023 21:54:40 CET | Business Wire | Press release

Share
Saudi Reaffirms Commitment to Bridging Global Divides, Driving Energy Transition, Inclusive Economic Growth at WEF23

Saudi Arabia reiterated its commitment to build bridges across geopolitical and economic divides at the World Economic Forum (WEF) 2023 Annual Meeting in Davos, Switzerland, last week.

His Highness Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs, led the Saudi delegation of nine ministers and high-level officials, and told the world that geopolitical stability is key to energy security, and the Kingdom has “become the meeting place between East and West.”

During the week, Saudi Arabia hosted a dialogue titled ‘Toward a Resilient Urban Resource Nexus,’ with key international public and private sector stakeholders from regional and global organizations discussing the sustainability of future cities.

His Highness Prince Faisal, Her Royal Highness Princess Reema, His Excellency Alswaha, His Excellency Alkhorayef and His Excellency Alibrahim participated in a multilateral meeting with WEF leadership, Klaus Schwab, Founder and Executive Chairman, and Børge Brende, President, to explore areas of mutual interest.

During the meeting, His Excellency Alswaha, Chairman of the Board of King Abdulaziz City for Science and Technology (KACST) and Chairman of the Board of The Research, Development and Innovation Authority (RDIA) and Brende, signed a Letter of Intent (LoI) to establish a new accelerator program to help ignite innovation in Saudi Arabia.

The Saudi delegates highlighted the Kingdom's role as a Pioneering Partner in the Forum's Global Collaboration Village, which will leverage the Metaverse to serve the global community.

Separately, the Ministry of Investment, in coordination with the Ministry of Energy and the Ministry of Industry and Mineral Resources, organized a high-level dialogue for executives from the energy, petrochemicals and mining sectors to discuss the impact of the energy transition, the role of petrochemical industries and investments needed to achieve net zero by 2060.

Meanwhile, Saudi Arabia’s Ministry of Economy and Planning – in collaboration with the WEF open innovation platform UpLink – launched a challenge to crowdsource transformative solutions to secure local food in countries impacted by low rainfall, drought and desertification.

The Food Ecosystems and Arid Climates Challenge is a global call for food entrepreneurs, start-ups, social ventures, and SMEs to submit solutions that incorporate low or high technologies or ancestral responses.

Also during the week, Saudi Arabia – represented by the Ministry of Economy and Planning – joined the WEF Jobs Consortium, a coalition of CEOs, IOs, ministers and other leaders with a common aim to promote a better future of work for all by enabling job creation and job transitions.

The Saudi Arabian delegation also engaged in a wide range of bilateral meetings, dialogues with global leaders, ministers and CEOs and – for the first time – public panel sessions as part of WEF’s Open Forum. These included discussions with high-level public and private sector representatives from several countries and were an opportunity to share the Kingdom’s vision while exploring potential partnerships and areas of collaboration.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005752/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye